Prof Dr Christof von Kalle Appointed Director of LCTR

The Luxembourg Institute of Health (LIH) has announced that Prof Dr Christof von Kalle has been appointed Director of the Luxembourg Center for Translational Research (LCTR) Fuerschungsklinik Lëtzebuerg, effective 1 December 2024. 

With a distinguished career spanning translational oncology, gene therapy and molecular medicine, Prof Dr von Kalle brings exceptional leadership and expertise to the 
institute. 

Previously the Founding Director of the Charité and Berlin Institute of Health Clinical Study Center, Prof Dr von Kalle is well-versed in fostering collaboration across academia, healthcare, and industry. 

According to the LIH, his leadership will be pivotal in driving the LCTR's mission to bridge research and clinical care, focusing on chronic diseases such as cancer, neurodegenerative disorders, and autoimmune conditions. 

Prof Dr von Kalle will lead the LCTR in its mission to deliver innovative research that bridges scientific discovery and patient care. LCTR plays a pivotal role as a national platform that unites clinicians, researchers and patients to foster cutting-edge clinical studies and transformative healthcare solutions. With its unique approach to digital health and translational medicine, LCTR is positioned to advance precision medicine and improve outcomes for patients in Luxembourg and beyond. 

In his new role, Prof Dr von Kalle will focus on expanding LCTR’s research capacity, fostering national and international collaborations, and strengthening the integration of healthcare and clinical research. He brings a wealth of leadership experience and a vision for innovation.

Prof Dr von Kalle’s stated: "The LCTR represents a remarkable convergence of innovation, collaboration, and patient-centred research. My goal is to ensure that our efforts at LCTR translate directly into improved patient care while positioning Luxembourg as a global leader in translational medicine. Together, we will build on this foundation and explore new frontiers in biomedical science." 

Under Prof Dr von Kalle’s leadership, the LCTR aims to address pressing healthcare challenges, including cancer, neurodegenerative diseases, and autoimmune disorders. By leveraging Luxembourg’s robust translational infrastructure, LCTR will continue to transform research insights into pioneering therapeutic solutions.